Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …

Patients with rheumatic diseases are at increased risk of infectious complications;
vaccinations are a critical component of their care. Disease-modifying antirheumatic drugs …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Objective To provide recommendations for the management of juvenile idiopathic arthritis
(JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations …

Objectives Recent insights supporting the safety of live-attenuated vaccines and novel
studies on the immunogenicity of vaccinations in the era of biological disease-modifying …

Background Conventional pharmacological therapies for the treatment of juvenile idiopathic
arthritis (JIA) consist of non-biological, disease-modifying antirheumatic drugs, among which …

The human papilloma virus (HPV) vaccines were introduced to reduce the incidence of
cervical cancer. The bivalent vaccine is effective against HPV-16,-18,-31,-33 and-45 while …

Methotrexate (MTX) is a readily accessible drug, first used in 1948 and employed for a wide
variety of indications since then. However, despite widespread off‐label use, FDA labeling …

It is well-established that immunocompromised people are at increased risk of HPV-related
disease compared with those who are immunocompetent. Prophylactic HPV sub-unit …

Patients with rheumatoid arthritis (RA) are at greater risk of infectious complications, which is
likely attributed both to medications used to treat RA, and to abnormalities in their immune …